These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1384 related items for PubMed ID: 18070147

  • 41. BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma.
    Ohori NP, Singhal R, Nikiforova MN, Yip L, Schoedel KE, Coyne C, McCoy KL, LeBeau SO, Hodak SP, Carty SE, Nikiforov YE.
    Cancer Cytopathol; 2013 Apr; 121(4):197-205. PubMed ID: 22887810
    [Abstract] [Full Text] [Related]

  • 42. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.
    Buitrago D, Keutgen XM, Crowley M, Filicori F, Aldailami H, Hoda R, Liu YF, Hoda RS, Scognamiglio T, Jin M, Fahey TJ, Zarnegar R.
    Ann Surg Oncol; 2012 Mar; 19(3):973-80. PubMed ID: 21879273
    [Abstract] [Full Text] [Related]

  • 43. Molecular Profiling of Papillary Thyroid Carcinoma in Korea with a High Prevalence of BRAFV600E Mutation.
    Lee SE, Hwang TS, Choi YL, Kim WY, Han HS, Lim SD, Kim WS, Yoo YB, Kim SK.
    Thyroid; 2017 Jun; 27(6):802-810. PubMed ID: 28293988
    [Abstract] [Full Text] [Related]

  • 44. BRAF V600E mutation does not predict recurrence after long-term follow-up in TNM stage I or II papillary thyroid carcinoma patients.
    Pelttari H, Schalin-Jäntti C, Arola J, Löyttyniemi E, Knuutila S, Välimäki MJ.
    APMIS; 2012 May; 120(5):380-6. PubMed ID: 22515292
    [Abstract] [Full Text] [Related]

  • 45. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.
    Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, Materazzi G, Elisei R, Santoro M, Miccoli P, Basolo F.
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4085-90. PubMed ID: 17785355
    [Abstract] [Full Text] [Related]

  • 46. Frequent BRAF V600E and Absence of TERT Promoter Mutations Characterize Sporadic Pediatric Papillary Thyroid Carcinomas in Japan.
    Oishi N, Kondo T, Nakazawa T, Mochizuki K, Inoue T, Kasai K, Tahara I, Yabuta T, Hirokawa M, Miyauchi A, Katoh R.
    Endocr Pathol; 2017 Jun; 28(2):103-111. PubMed ID: 28176151
    [Abstract] [Full Text] [Related]

  • 47. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas.
    Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, Marino C, Avenia N, Rossi ED, Fadda G, Cavaliere A, Ribacchi R, Falorni A, Pontecorvi A, Pacini F, Pinchera A, Santeusanio F.
    J Clin Endocrinol Metab; 2004 May; 89(5):2414-20. PubMed ID: 15126572
    [Abstract] [Full Text] [Related]

  • 48. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.
    Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Máximo V, Botelho T, Seruca R, Sobrinho-Simões M.
    Oncogene; 2003 Jul 17; 22(29):4578-80. PubMed ID: 12881714
    [Abstract] [Full Text] [Related]

  • 49. BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion.
    Chakraborty A, Narkar A, Mukhopadhyaya R, Kane S, D'Cruz A, Rajan MG.
    Endocr Pathol; 2012 Jun 17; 23(2):83-93. PubMed ID: 22105775
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas.
    Chuang TC, Chuang AY, Poeta L, Koch WM, Califano JA, Tufano RP.
    Head Neck; 2010 Feb 17; 32(2):229-34. PubMed ID: 19626635
    [Abstract] [Full Text] [Related]

  • 55. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.
    Abubaker J, Jehan Z, Bavi P, Sultana M, Al-Harbi S, Ibrahim M, Al-Nuaim A, Ahmed M, Amin T, Al-Fehaily M, Al-Sanea O, Al-Dayel F, Uddin S, Al-Kuraya KS.
    J Clin Endocrinol Metab; 2008 Feb 17; 93(2):611-8. PubMed ID: 18000091
    [Abstract] [Full Text] [Related]

  • 56. BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas.
    Takano T, Ito Y, Hirokawa M, Yoshida H, Miyauchi A.
    Br J Cancer; 2007 May 21; 96(10):1549-53. PubMed ID: 17453004
    [Abstract] [Full Text] [Related]

  • 57. [Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].
    Vasil'ev EV, Rumiantsev PO, Saenko VA, Il'in AA, Poliakova EIu, Nemtsova MV, Zaletaev DV.
    Mol Biol (Mosk); 2004 May 21; 38(4):642-53. PubMed ID: 15456136
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population.
    Brzeziańska E, Pastuszak-Lewandoska D, Wojciechowska K, Migdalska-Sek M, Cyniak-Magierska A, Nawrot E, Lewiński A.
    Neuro Endocrinol Lett; 2007 Aug 21; 28(4):351-9. PubMed ID: 17693984
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 70.